Key Highlights

  • The FDA granted Breakthrough Therapy Designation for 64Cu-SAR-bisPSMA PET imaging in men with suspected prostate cancer recurrence.
  • In the investigator-led Co-PSMA study, 78% of participants were positive on the copper-64 agent, compared with 36% on gallium-68 PSMA-11.
  • The Phase III AMPLIFY and CLARIFY trials have completed recruitment, with topline data expected in the first half of CY2027.
  • The imaging agent remains unregistered, and the designation does not guarantee FDA approval.

Clarity Pharmaceuticals (ASX:CU6) has received Breakthrough Therapy designation from the United States Food and Drug Administration for its copper-64 SAR-bisPSMA imaging agent, according to an announcement dated 12 November 2026. The designation applies to positron emission tomography imaging of prostate-specific membrane antigen positive lesions in men with suspected cancer recurrence based on elevated prostate-specific antigen levels. The company describes it as the first Breakthrough Therapy designation granted for PSMA PET imaging. The milestone is regulatory rather than a Marketing approval, and the agent remains unregistered in the United States and Australia.

What the designation provides

Breakthrough Therapy designation is a regulatory pathway for serious conditions where early clinical evidence suggests a candidate may offer meaningful improvement over existing options. Holders gain access to the features of Fast Track designation, more intensive FDA guidance on development programs and greater senior-level involvement during review. The designation also makes a product a likely candidate for Priority Review, which can shorten the FDA review period once a New Drug Application is filed.

The designation, however, does not amount to approval. It is granted on preliminary evidence, and the FDA can still require pivotal data before deciding whether the agent may enter the market. The company has stated that neither the safety nor the efficacy of its product has been assessed by the FDA or the Therapeutic Goods Administration, and it has cautioned that there is no guarantee the product will become commercially available.

The clinical evidence behind the decision

The core support for the designation comes from Co-PSMA, an investigator-initiated trial led by Prof Louise Emmett at St Vincent's Hospital in Sydney. The study compared the copper-64 agent with gallium-68 PSMA-11 in 50 men with prostate-specific antigen levels between 0.2 and 0.75 ng/mL after radical prostatectomy. On a per-patient basis, 78% of participants were positive on next-day copper-64 imaging, compared with 36% on gallium-68 imaging. The mean lesion count per patient was 1.26 for the copper-64 agent against 0.48 for the comparator, a difference the trial reported as statistically significant.

The COBRA study adds a second dataset, although its efficacy analysis is considerably smaller. Of 52 enrolled participants, 42 were included in efficacy calculations, all with negative or equivocal findings on standard imaging. Correct detection rates ranged from 26.2% to 33.3% on next-day imaging across central readers, with confidence intervals that span a wide range. Biopsies were performed in only nine patients, seven of whom were positive on histopathology. The composite reference standard and the small sample sizes will matter when regulators weigh these results.

Pivotal trials and the road ahead

Two registrational Phase III studies are central to the next stage. AMPLIFY, which enrols men with rising or detectable PSA after definitive treatment, reached its target of about 220 participants in March 2026. CLARIFY, which examines men with high-risk prostate cancer before radical prostatectomy, achieved its enrolment target in October 2026. Both trials are in follow-up, and topline data are anticipated in the first half of calendar 2027. The company intends to use the final results to support an application for approval of the agent as a diagnostic imaging product.

The commercial backdrop is sizeable. The company estimates that PSMA PET sales in the United States are around US$2 billion a year and could exceed US$3 billion by 2029, a figure that has not been independently verified. The American Cancer Society projects about 333,830 new prostate cancer cases in the United States in 2026. Competition is already established through two FDA-approved PSMA PET agents, and any new entrant will need to show a clear clinical advantage in that setting.

Final Word

Breakthrough Therapy designation adds regulatory weight to the copper-64 program, yet it leaves the central questions unresolved. The early data show a higher detection rate than the comparator, but the evidence comes from small studies, one of them investigator-initiated, and the pivotal results will carry the decisive weight. The next readout in 2027 will show whether the detection gains hold in larger registrational populations and whether the agent can move from an unregistered product to an approved clinical option.